Alpha-Lipoic Acid for PCOS: Insulin Sensitivity and the ALA-Inositol Trials

Does alpha-lipoic acid actually improve insulin resistance in PCOS?

A 2024 systematic review and meta-analysis found alpha-lipoic acid significantly reduced fasting blood sugar across 7 randomized controlled trials (standardized mean difference −0.60) and HOMA-IR across 4 of those trials (SMD −2.03) in women with PCOS (Abu-Zaid et al., 2024). That HOMA-IR effect size is large on paper, but the same review rated the certainty of that specific finding as low, because of high inconsistency between the four trials that measured it (I² = 96%). The same analysis found no significant difference between ALA and control groups for body mass index, insulin, estrogen, FSH, LH, testosterone, or cholesterol markers. ALA moves two glucose-pathway numbers with real consistency; it does not move the hormonal picture PCOS is usually diagnosed by.

What dose was actually used, and for how long?

Eight hundred milligrams of ALA per day is the dose behind the strongest combination-trial evidence, almost always paired with myo-inositol rather than given alone. A retrospective study of 71 women compared 800 mg ALA plus either 2,000 mg or 1,000 mg of myo-inositol daily for 6 months: menstrual cyclicity improved in 71.2% of women overall, and 85.7% of those on the higher inositol dose reported improved regularity versus 50% on the lower dose (p<0.01) (Fruzzetti et al., 2020). A separate long-term follow-up of the same ALA-plus-inositol combination found cycle length significantly reduced at 6, 12, and 24 months, with insulin response to an oral glucose tolerance test improved at 6 and 18 months — though HOMA-IR and fasting insulin themselves stayed unchanged across the same period. Lower doses appear in other trials: a d-chiro-inositol combination trial used only 300 mg of ALA alongside 500 mg of DCI for 3 months (Genazzani et al., 2022), and a 2026 ovulation trial used 1,800 mg/day of ALA alone alongside letrozole. There is no single “the” ALA dose in this literature — 300 mg, 800 mg, and 1,800 mg have each been tested for different outcomes and different durations.

Does ALA work differently depending on family history of diabetes?

Women with a family history of diabetes showed the largest insulin-related improvements from ALA in two separate trials by the same research group. In overweight or obese women with PCOS, ALA alone significantly improved insulin sensitivity and liver clearance of insulin, and the effect was greater specifically in those with a familial diabetes background, who also saw larger drops in liver enzymes (AST and ALT) (Genazzani et al., 2024). A related trial combining d-chiro-inositol with ALA found the same pattern: hepatic insulin extraction — a measure of how well the liver clears circulating insulin — was reduced in women with familial diabetes at baseline, and DCI plus ALA restored it along with reducing LH, androstenedione, and liver enzymes (Genazzani et al., 2022). If insulin resistance runs in your family, this is the subgroup the evidence speaks to most directly; if it does not, expect a smaller or unproven effect.

Does ALA help with ovulation or fertility outcomes?

A 2026 randomized controlled trial of 151 infertile women with PCOS found that adding 1,800 mg/day of ALA to letrozole increased ovulation per cycle to 92.2%, compared with 71.9% on letrozole alone, and pregnancy per cycle was also significantly higher in the ALA group (Sallam et al., 2026). This is a genuine, PCOS-specific finding from a reasonably sized trial — not an extrapolation — but it is one trial testing one specific combination under medical supervision as part of an ovulation-induction cycle, not a basis for adding ALA to any fertility plan on your own. Talk to a fertility specialist about whether this combination applies to your specific treatment plan rather than starting it independently.

What actually changes for lean PCOS?

None of the trials behind Table 1 selected participants specifically for a lean phenotype — most recruited overweight or obese women, and the strongest ALA-alone findings (liver insulin clearance, fasting glucose) came from an overweight/obese cohort specifically. Because ALA’s best-documented mechanism is improving insulin handling, it has the clearest rationale for lean PCOS only when insulin resistance is confirmed by testing rather than assumed from body size. For lean PCOS driven by adrenal or hypothalamic-pituitary patterns rather than hyperinsulinaemia, no trial here offers evidence either way.

Who should not expect alpha-lipoic acid to help?

If your priority is androgen symptoms — acne, hirsutism, or hair loss — no trial reviewed here measured or found an effect on testosterone or androgen-driven symptoms from ALA alone; the 2024 meta-analysis found no significant hormonal difference at all. If you are looking for a weight-loss supplement, the same meta-analysis found no significant BMI difference between ALA and control groups — any change reported in individual small trials did not hold up when pooled. And if you already have well-managed insulin resistance on metformin or myo-inositol alone, ALA’s added value on top of an existing regimen has not been tested in a trial designed to answer that specific question.

What is the realistic timeline?

The glucose and insulin effects in the 2024 meta-analysis come from trials generally running 8 to 12 weeks. The menstrual-regularity and long-term metabolic findings from the ALA-plus-inositol combination trials took considerably longer — 6 months for the first measurable improvement in cycle regularity, with continued change tracked out to 24 months (Fruzzetti et al., 2020). If you are taking ALA for glucose markers, expect to recheck labs at 8–12 weeks; if you are taking the combination for cycle regularity, the trials that showed benefit ran six months before drawing a conclusion.

You may see PCOS referred to as polyendocrine metabolic ovarian syndrome (PMOS) after a 2026 global consensus of more than 50 organisations renamed it. Nothing about the ALA evidence above changed with the name — this article uses PCOS because that is still what readers search.

For the full trial-evidence ranking across the commonly used PCOS supplements, see our ranked review of PCOS supplement evidence, or browse the supplements section directly. If you are specifically comparing insulin-sensitising options, inositol’s dose, ratio, and side effects are covered in more depth on its own page, and the fuller mechanism behind why insulin resistance develops in PCOS — along with what else moves HOMA-IR — is covered in treating insulin resistance in PCOS. Probiotics and melatonin are graded separately for readers comparing gut- or sleep-focused options against this one. For a direct side-by-side against the other supplement it’s most often compared to, see alpha-lipoic acid compared against berberine.

Common questions